The Norwegian start-up recently announced a September debut of an omega-3 form it is promoting on the back of high-quality salmon sourcing and ongoing clinical trials demonstrating LDL cholesterol benefits.
The patented extraction process reportedly enables the removal of omega-3s from fresh salmon rather than the fish meal that is the source of most omega-3 ingredients.
This meant extracting the virgin oil within 24 hours of the fish being killed.
Larry Kolb, president of TSI Health Sciences, described Hofseth’s omega-3 offering as “the best ingredient opportunity we have seen to effectively deliver a point of difference to this category and marketplace”..
“We look forward to building awareness and sales of Hofseth’s proprietary salmon oil ingredients through our global marketing offices,” he added.
Sjur Jenssen, CEO of Hofseth Biocare, complimented TSI’s commitment to service and science-based support for brand owners.
“While the industry is focused on the specification, we have concentrated on human clinical trials that have shown activity far beyond anything we know to exist in the marketplace. In addition, our exceptional supply chain and patented processing method adds to our overall uniqueness” said Jenssen.